Eli Lilly and Company (LLY) Shares are Down -1.6%

Eli Lilly and Company (LLY) has risen sharply, recording gains of 2.39% in the past 4 weeks. However, the stock has corrected -1.6% in the past 1 week, providing a good buying opportunity on dips. Eli Lilly and Company (LLY) : During the past 4 weeks, traders have been relatively bearish on Eli Lilly and Company (LLY), hence the stock is down -0.1% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.02% relative to the S&P 500.

Eli Lilly and Company (NYSE:LLY): The stock opened at $82.42 on Friday but the bulls could not build on the opening and the stock topped out at $82.52 for the day. The stock traded down to $81.04 during the day, due to lack of any buying support eventually closed down at $81.56 with a loss of -1.04% for the day. The stock had closed at $82.42 on the previous day. The total traded volume was 5,886,901 shares.

The stock has recorded a 20-day Moving Average of 0.33% and the 50-Day Moving Average is 4.93%. Eli Lilly and Company is up 10.06% in the last 3-month period. Year-to-Date the stock performance stands at -1.88%.

Eli Lilly and Company (LLY) : The highest level Eli Lilly and Company (LLY) is projected to reach is $116 for the short term and the lowest estimate is at $55. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $95.42 and the possibility the share price can swing is $16.37.


Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.